IL6 and COVID-19: A subgroup of patients with severe COVID-19 may have a cytokine storm syndrome, and treatment of hyperinflammation using existing therapies such as IL-6 inhibitors (tocilizumab and sarilumab), and interleukin 1 receptor antagonists (IL-1RA) (anakinra) may reduce the mortality [39].